

IFW

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, P.O. Box 1450, Alexandria, VA, 22313-1450.

Nancy Yorke

Signature

Nancy Yorke

Date

Aug 1, 2008



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Aiyar et al.

Serial No.: 10/553,117

Case No.: MS0019

Art Unit: TBA

Filed: October 13, 2005

Examiner: TBA

For: SPLICE VARIANTS OF HUMAN VOLTAGE-
GATED CALCIUM CHANNEL $\alpha 2\beta$ -2 SUBUNIT
DESIGNATED $\alpha 2\beta$ 2-A AND $\alpha 2\beta$ 2-B

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION UNDER 37 CFR §1.8(b) REGARDING
NOTICE OF ABANDONMENT OF APPLICATION

Sir:

This Communication under 37 CFR §1.8(b) is in response to the Notice of Abandonment dated June 27, 2008 for the above captioned application. The Notice of Abandonment states that the Applicant has failed to respond to a notification of Missing Requirement mailed November 2, 2006 within the time period set therein.

REMARKS

Applicants respectfully submit that the Notice of Abandonment for the present application is in error. Applicants respectfully request that the Notice of Abandonment and record of Abandonment be withdrawn, that the Submission of Sequence Statement originally filed December 19, 2006 be accepted and entered as timely filed, and that examination on the merits proceed.

Applicants received November 6, 2006 a "Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures" (Notification) that was mailed November 2, 2006. The Notification provided a two month time with which to respond. The Notification required an initial computer readable form (CRF) and paper copy of the Sequence Listing, an amendment directing its entry into the application and a statement that the CRF and paper copies were identical. It should be noted that Applicants had previously submitted the CRF and paper copy of the Sequence Listing and the statement when the application was originally filed October 13, 2005. Notwithstanding, Applicants submitted a timely response (Response), a copy of which is enclosed herewith, on December 19, 2006, which Response included the CRF and paper copies, sequence statement, and an amendment directing its entry into the application. Applicants received the stamped postcard acknowledging receipt by the USPTO on December 22, 2006, a copy of which is attached herewith, on December 28, 2006.

The undersigned attorney hereby certifies that the original of the attached Response was submitted in response to the Notification. The undersigned attorney further states that they had a reasonable basis to expect that the Response would be timely filed on December 19, 2006 by being deposited with the U.S. Postal Service with sufficient postage as First Class Mail addressed to the Assistant Commissioner for Patents, Washington DC 20231 under the provisions of 37 CFR §1.8. The Response also bears a stamped certification of mailing in accordance with 37 CFR §1.8(a)(1)(ii) with the mailing date of December 19, 2006. The undersigned attorney avers that based on standard operating procedures of their employer they had a reasonable basis to expect that the correspondence would in fact be mailed on the date indicated.

In reviewing the Transaction History for this application in PAIR, Applicants note that the Response submitted on December 19, 2006 was not entered, however, the previous sequence submission of October 13, 2005 is included within the File Wrapper. In an effort to ensure the completeness of the Transaction History and File Wrapper for this application, it should be noted that the IDS submitted on February 28, 2007, a copy of which is enclosed

herewith, is not included in the Transaction History, but is included with the File Wrapper. A copy of the postcard receipt is included herewith dated March 5, 2007. A copy of the Transaction History and File Wrapper is also enclosed herewith. Applicants request that the Transaction History be amended to include the IDS submission as well.


CONDITIONAL PETITION

Applicants hereby make a Conditional Petition for any relief available to correct any defect in connection with this filing, or any defect remaining in this application after this filing. The Commissioner is authorized to charge deposit account 13-2755 for the petition fee and any other fee(s) required to effect this Conditional Petition.

CONCLUSION

Having demonstrated that the outstanding Notification was responded to in a timely fashion, Applicants respectfully request that the Notice and record of Abandonment be withdrawn and that prosecution of the application on the merits be allowed to proceed.

Respectfully submitted,

By 
Joan E. Switzer
Reg. No. 34,740
Attorney for Applicant

MERCK & CO., INC.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-5616


Date: August 1, 2008

Attachments: Copy of Response mailed December 19, 2006
Copy of Postcard acknowledged by USPTO on December 22, 2006
Copy of PAIR Transaction History and File Wrapper for 10/553,117
Copy of IDS mailed February 28, 2007
Copy of Postcard acknowledged by USPTO on March 5, 2007

P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY	V. Kohli	DATE	12/19/2006
CASE NUMBER/	MS0019P	SERIAL NUMBER	10/553,117
DATE FILED	10/13/2005		
APPLICANT	Aiyar et al.		
EXPRESS MAIL NO.	-----		


The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:



- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECT
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☐ INFORMATION DISCLOSURE STATEMENT
- ☐ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET

✓ SUBMISSION OF SEQUENCE STATEMENT

© 2005 USPS recycled



Rahway, New Jersey 07065 - 0907

P.O. Box 2000

PATENT DEPARTMENT, RY60-30

PATENT DOCKET

2006 DEC 28 AM 9:28

RECEIVED
MERCK & CO., INC

DOCKETED

JAN 11 4 11AM

001 SCHEP81



19/553,117

Splice variants of human voltage-gated calcium channel alpha2beta-2 subunit
designated - alpha2beta-a and alpha2beta2-b07-23-
2008::08:29:02**Transaction History**

Date	Transaction Description
06-02-2007	Abandonment -- Inc. Application under Rule 53(b) - Filing Fee Paid
03-13-2006	Cleared by OIPE CSR
03-13-2006	Cleared by OIPE CSR
03-13-2006	Cleared by OIPE CSR
10-13-2005	CRF Disk Has Been Received by Preexam / Group / PCT
10-13-2005	Initial Exam Team nn

[Close Window](#)

10/553,117

Splice variants of human voltage-gated calcium channel alpha2beta-2 subunit
designated - alpha2beta-a and alpha2beta2-b07-23-
2008::08:21:51

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click PDF.

Bibliographic Data

Mail Room Date	Document Code	Document Description	Document Category	Page Count
06-27-2008	ABN	Abandonment	PROSECUTION	1
03-05-2007	IDS	Information Disclosure Statement (IDS) Filed	PROSECUTION	11
03-05-2007	FOR	Foreign Reference	PRIOR ART	177
03-05-2007	FOR	Foreign Reference	PRIOR ART	73
03-05-2007	FOR	Foreign Reference	PRIOR ART	83
03-05-2007	FOR	Foreign Reference	PRIOR ART	258
03-05-2007	FOR	Foreign Reference	PRIOR ART	48
03-05-2007	NPL	NPL Documents	PRIOR ART	8
03-05-2007	NPL	NPL Documents	PRIOR ART	35
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	20
03-05-2007	NPL	NPL Documents	PRIOR ART	18
03-05-2007	NPL	NPL Documents	PRIOR ART	2
03-05-2007	NPL	NPL Documents	PRIOR ART	7
03-05-2007	NPL	NPL Documents	PRIOR ART	11
03-05-2007	NPL	NPL Documents	PRIOR ART	8
03-05-2007	NPL	NPL Documents	PRIOR ART	10
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	49
03-05-2007	NPL	NPL Documents	PRIOR ART	4
03-05-2007	NPL	NPL Documents	PRIOR ART	2
03-05-2007	NPL	NPL Documents	PRIOR ART	56
03-05-2007	NPL	NPL Documents	PRIOR ART	17
03-05-2007	NPL	NPL Documents	PRIOR ART	14
03-05-2007	NPL	NPL Documents	PRIOR ART	4
03-05-2007	NPL	NPL Documents	PRIOR ART	4
03-05-2007	NPL	NPL Documents	PRIOR ART	8
03-05-2007	NPL	NPL Documents	PRIOR ART	9
03-05-2007	NPL	NPL Documents	PRIOR ART	4
03-05-2007	NPL	NPL Documents	PRIOR ART	8
03-05-2007	NPL	NPL Documents	PRIOR ART	6
03-05-2007	NPL	NPL Documents	PRIOR ART	11
03-05-2007	NPL	NPL Documents	PRIOR ART	8
03-05-2007	NPL	NPL Documents	PRIOR ART	10
03-05-2007	NPL	NPL Documents	PRIOR ART	12
03-05-2007	NPL	NPL Documents	PRIOR ART	8
03-05-2007	NPL	NPL Documents	PRIOR ART	3
03-05-2007	NPL	NPL Documents	PRIOR ART	6
03-05-2007	NPL	NPL Documents	PRIOR ART	4
03-05-2007	NPL	NPL Documents	PRIOR ART	9
03-05-2007	NPL	NPL Documents	PRIOR ART	13
03-05-2007	NPL	NPL Documents	PRIOR ART	9
03-05-2007	NPL	NPL Documents	PRIOR ART	9
03-05-2007	NPL	NPL Documents	PRIOR ART	12
03-05-2007	NPL	NPL Documents	PRIOR ART	11
03-05-2007	NPL	NPL Documents	PRIOR ART	8
03-05-2007	NPL	NPL Documents	PRIOR ART	7
03-05-2007	NPL	NPL Documents	PRIOR ART	12
03-05-2007	NPL	NPL Documents	PRIOR ART	1
03-05-2007	NPL	NPL Documents	PRIOR ART	8

03-05-2007	NPL	NPL Documents	PRIOR ART	7
03-05-2007	NPL	NPL Documents	PRIOR ART	19
03-05-2007	NPL	NPL Documents	PRIOR ART	6
03-05-2007	NPL	NPL Documents	PRIOR ART	7
03-05-2007	NPL	NPL Documents	PRIOR ART	16
03-05-2007	NPL	NPL Documents	PRIOR ART	6
03-05-2007	NPL	NPL Documents	PRIOR ART	4
03-05-2007	NPL	NPL Documents	PRIOR ART	6
03-05-2007	NPL	NPL Documents	PRIOR ART	15
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	2
03-05-2007	NPL	NPL Documents	PRIOR ART	14
03-05-2007	NPL	NPL Documents	PRIOR ART	6
03-05-2007	NPL	NPL Documents	PRIOR ART	3
03-05-2007	NPL	NPL Documents	PRIOR ART	3
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	7
03-05-2007	NPL	NPL Documents	PRIOR ART	3
03-05-2007	NPL	NPL Documents	PRIOR ART	9
03-05-2007	NPL	NPL Documents	PRIOR ART	7
03-05-2007	NPL	NPL Documents	PRIOR ART	16
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	9
03-05-2007	NPL	NPL Documents	PRIOR ART	2
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	10
03-05-2007	NPL	NPL Documents	PRIOR ART	6
03-05-2007	NPL	NPL Documents	PRIOR ART	3
03-05-2007	NPL	NPL Documents	PRIOR ART	9
03-05-2007	NPL	NPL Documents	PRIOR ART	6
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	6
03-05-2007	NPL	NPL Documents	PRIOR ART	3
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	4
03-05-2007	NPL	NPL Documents	PRIOR ART	2
03-05-2007	NPL	NPL Documents	PRIOR ART	3
03-05-2007	NPL	NPL Documents	PRIOR ART	8
03-05-2007	NPL	NPL Documents	PRIOR ART	4
03-05-2007	NPL	NPL Documents	PRIOR ART	16
03-05-2007	NPL	NPL Documents	PRIOR ART	11
03-05-2007	NPL	NPL Documents	PRIOR ART	9
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	10
03-05-2007	NPL	NPL Documents	PRIOR ART	3
03-05-2007	NPL	NPL Documents	PRIOR ART	3
03-05-2007	NPL	NPL Documents	PRIOR ART	5
03-05-2007	NPL	NPL Documents	PRIOR ART	5
11-02-2006	PEFN	Pre-Exam Formalities Notice	PROSECUTION	2
02-22-2006	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	4
01-13-2006	LET.	Miscellaneous Incoming Letter	PROSECUTION	2
01-13-2006	OATH	Oath or Declaration filed	PROSECUTION	3
12-22-2005	IDS	Information Disclosure Statement (IDS) Filed	PROSECUTION	4
12-22-2005	FOR	Foreign Reference	PRIOR ART	10

12-22-2005	FOR	Foreign Reference	PRIOR ART	17
12-22-2005	FOR	Foreign Reference	PRIOR ART	23
12-22-2005	FOR	Foreign Reference	PRIOR ART	14
12-22-2005	FOR	Foreign Reference	PRIOR ART	5
12-22-2005	FOR	Foreign Reference	PRIOR ART	4
12-22-2005	FOR	Foreign Reference	PRIOR ART	6
12-22-2005	FOR	Foreign Reference	PRIOR ART	5
12-22-2005	FOR	Foreign Reference	PRIOR ART	4
12-22-2005	FOR	Foreign Reference	PRIOR ART	8
12-22-2005	FOR	Foreign Reference	PRIOR ART	5
12-22-2005	FOR	Foreign Reference	PRIOR ART	8
12-22-2005	FOR	Foreign Reference	PRIOR ART	11
10-13-2005	TRNA	Transmittal of New Application	PROSECUTION	2
10-13-2005	SPEC	Specification	PROSECUTION	75
10-13-2005	CLM	Claims	PROSECUTION	5
10-13-2005	ABST	Abstract	PROSECUTION	2
10-13-2005	DRW	Drawings-only black and white line drawings	PROSECUTION	1
10-13-2005	SEQLIST	Sequence Listing	PROSECUTION	8
10-13-2005	OATH	Oath or Declaration filed	PROSECUTION	9
10-13-2005	IMIS	Miscellaneous Internal Document	PROSECUTION	1
10-13-2005	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	1
10-13-2005	A.PE	Preliminary Amendment	PROSECUTION	1
10-13-2005	SPEC	Specification	PROSECUTION	1
10-13-2005	CLM	Claims	PROSECUTION	4
10-13-2005	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	1
10-13-2005	NPL	NPL Documents	PROSECUTION	106
10-13-2005	ARTIFACT	Artifact sheet indicating an item has been filed which cannot be scanned	PROSECUTION	1
10-13-2005	CRFL	CRF Sequence Listing Filed	PROSECUTION	1
10-13-2005	SEQLIST	Sequence Listing	PROSECUTION	9
09-13-2005	IMIS	Miscellaneous Internal Document	PROSECUTION	1
09-13-2005	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	1
09-13-2005	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	1
09-13-2005	WCLM	Claims Worksheet (PTO-2022)	PROSECUTION	1

[Close Window](#)

P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY	V. Kohli	DATE	02/28/2007
CASE NUMBER/ MS0019P	SERIAL NUMBER 10/553,117		
DATE FILED		10/13/2005	
APPLICANT		Aiyar et al.	
EXPRESS MAIL NO.		-----	

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:


- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☐ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET



DOCKETED
MAR 13 2007


2007 MAR -9 PM 1:20

DOCKETED




Merck & Co., Inc.
PATENT DEPARTMENT, RY60-30
P.O. Box 2000
Rahway, New Jersey 07065 - 0907

© 2005 USPS recycled



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Aiyar et al.



Serial No. 10/553,117

Filed: October 13, 2005

For: SPLICE VARIANTS OF HUMAN VOLTAGE-GATED
CALCIUM CHANNEL $\alpha 2\beta$ -2 SUBUNIT DESIGNATED
 $\alpha 2\beta$ 2-A AND $\alpha 2\beta$ 2-BArt Unit: T/B/AExaminer: T/B/ACommissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By J. Schiffman Date 2/28/07

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Vineet Kohli

Attorney _____ For Applicant(s)

Reg. No. 37,003

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3889

Date: February 28, 2007

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/553,117
				Filing Date	October 13, 2005
				First Named Inventor	Aiyar et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	8	Attorney Docket Number	MS0019P

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	A	US2002/0147309		Lipscombe et al.	10/10/2002
	B	5,571,893		Baker et al.	11/05/1996
	C	5,569,825		Lonberg et al.	10/29/1996
	D	5,567,610		Borrebaeck et al.	10/22/1996
	E	5,565,354		Ostberg et al.	10/15/1996
	F	5,559,004		Steinhardt et al.	09/24/1996
	G	5,429,921		Harpold et al.	07/04/1995
	H	5,399,346		Anderson et al.	03/21/1995
	I	5,312,928		Goldin et al.	05/17/1994
	J	5,225,539		Winter et al.	07/06/1993
	K	4,946,778		Ladner et al.	08/07/1990
	L	4,816,567		Cabilly et al.	03/28/1989
	M	4,642,285		Halbert et al.	02/10/1987
	N	4,376,110		David et al.	03/08/1983

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number		
	O	PCT	WO 01/70949	Graham et al.	09/27/2001
	P	PCT	WO 92/04381	Harris et al.	03/19/1992
	Q	EP	EP 0 125 023	Cabilly et al.	06/05/1991
	R	PCT	WO 87/02671	Robinson et al.	05/07/1987
	S	PCT	WO 86/01533	Neuberger et al.	03/13/1986

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE**STATEMENT BY APPLICANT***(use as many sheets as necessary)***COMPLETE IF KNOWN**

Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	10/553,117
	October 13, 2005
	Aiyar et al.
Attorney Docket Number	MS0019P

Sheet

2

of

8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	1	Tsien et al., "Multiple Types of Neuronal Calcium Channels and Their Selective Modulation", Trends Neurosci., 11(10):431-438, 1988
	2	Catterall, W. A., "Structure and Regulation of Voltage-Gated Ca ²⁺ Channels", Annual Rev. Cell Dev. Biol., 16:521-555, 2000
	3	Llinas et al., "Distribution and Functional Significance of the P-type, Voltage-dependent Ca ²⁺ Channels in the Mammalian Central Nervous System", Trends Neurosci., 15(9):351-355, 1992
	4	Hess, P., "Calcium Channels in Vertebrate Cells", Annual Review Neurosci., 56:337-356, 1990
	5	Bean, B. P., "Classes of Calcium Channels in Vertebrate Cells", Annual. Rev. Physiol., 51:367-384, 1989
	6	Hille, B., Ion Channels of Excitable Membranes, 3rd Ed., Sinauer Associates, Sunderland, Mass., 2001
	7	Marais et al., "Calcium Channel $\alpha 2\delta$ Subunits - Structure and Gabapentin Binding", Molecular Pharmacology, 59(5):1243-1248, 2001
	8	Dunlap et al., "Exocytotic Ca ²⁺ Channels in Mammalian Central Neurons", Trends Neurosci., 18(2):89-98, 1995
	9	Varadi et al., "Molecular Determinants of Ca ²⁺ Channel Function and Drug Action", Trends Pharmacol. Sci., 16:43-49, 1995
	10	Nooney et al., "Identifying Neuronal non-L Ca ²⁺ channels - More than Stamp Collecting?", Trends Pharmacol. Sci., 18:363-371, 1997
	11	Perez-Reyes et al., "Molecular Characterization of a Neuronal Low-voltage-activated T-type Calcium Channel", Nature, 391:896-900, 1998
	12	DeWaard et al., "Structural and Functional Diversity of Voltage-activated Calcium Channels", Ion Channels, ed. T. Narahashi, pages 41-87, Plenum Press, New York, 1996
	13	Catterall, W. A., "Excitation-Contraction Coupling in Vertebrate Skeletal Muscle: A Tale of Two Calcium Channels", Cell, 64:871-874, 1991
	14	Catterall, W. A., "Functional Subunit Structure of Voltage-Gated Calcium Channels", Science, 253:1499-1500, 1991
	15	Hofmann et al., "Voltage-Dependent Calcium Channels: From Structure to Function", Rev. Physiol. Biochem. Pharmacol., 139:33-87, 1999

Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/553,117
				Filing Date	October 13, 2005
				First Named Inventor	Aiyar et al.
				Group Art Unit	
				Examiner Name	
Sheet	3	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	16	Lacinova et al., "Low Voltage Activated Calcium Channels: from Genes to Function", Gen. Physiol. Biophys., 19:121-136, 2000
	17	Perez-Reyes, E. & Schneider, "Molecular Biology of Calcium Channels", Kidney International, 48:1111-1124, 1995
	18	Ellis et al., "Sequence and Expression of mRNAs Encoding the $\alpha 1$ and $\alpha 2$ Subunits of a DHP-Sensitive Calcium Channel", Science, 241:1661-1664, 1988
	19	Schmid et al., "Immunochemical Analysis of Subunit Structures of 1,4-Dihydropyridine Receptors Associated with Voltage-Dependent Ca^{2+} Channels in Skeletal, Cardiac, and Smooth Muscles", Biochemistry, 25:3492-3495, 1986
	20	Angelotti & Hofmann, "Tissue-specific Expression of Splice Variants of the Mouse Voltage-gated Calcium Channel $\alpha 2/\delta$ subunit", Febs Lett., 397: 331-337, 1996
	21	Klugbauer et al., "Molecular Diversity of the Calcium Channel $\alpha 2\delta$ Subunit", J. Neuroscience, 19:(2)684-691, 1999
	22	DeJongh et al., "Subunits of Purified Calcium Channels", J. Biol. Chem., 265(25):14738-14741, 1990
	23	Jay et al., "Structural Characterization of the Dihydropyridine-sensitive Calcium Channel $\alpha 2$ -Subunit and the Associated δ Peptides", J. Biol. Chem., 266(5):3287-3293, 1991
	24	Gao et al., "Functional Properties of a New Voltage-dependent Calcium Channel $\alpha 2\delta$ Auxiliary Subunit Gene (<i>CACNA2D2</i>)", J. Biol. Chem., 275(16):12237-12242, 2000
	25	Gurnett et al., "Dual Function of the Voltage-Dependent Ca^{2+} Channel $\alpha 2\delta$ Subunit in Current Stimulation and Subunit Interaction", Neuron, 16:431-440, 1996
	26	Felix et al., "Dissection of Functional Domains of the Voltage-Dependent Ca^{2+} Channel $\alpha 2\delta$ Subunit", J. Neurosci., 17(18):6884-6891, 1997
	27	Gee et al., The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the $\alpha 2\delta$ Subunit of a Calcium Channel", J. Biol. Chem., 271(10):5768-5776, 1996
	28	Bito et al., " Ca^{2+} -dependent Regulation in Neuronal Gene Expression", Curr. Opin. Neurobiol., 7:419-429, 1997
	29	Toyota et al., "Inactivation of <i>CACNA1G</i> , a T-Type Calcium Channel Gene, by Aberrant Methylation of Its 5' CpG Island in Human Tumors", Cancer Research, 59:4535-4541, 1999

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/553,117	
			Filing Date	October 13, 2005	
			First Named Inventor	Aiyar et al.	
			Group Art Unit		
			Examiner Name		
Sheet	4	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	30	Charlier et al., "A Pore Mutation in a Novel KQT-like Potassium Channel Gene in an Idiopathic Epilepsy Family", Nature Genet., 18:53-55, 1998
	31	Singh et al., "A Novel Potassium Channel Gene, <i>KCNQ2</i> , is Mutated in an Inherited Epilepsy of Newborns", Nature Genet., 18:25-29, 1998
	32	Biervert et al., "A Potassium Channel Mutation in Neonatal Human Epilepsy", Science, 279:403-406, 1998
	33	Burgess et al., "Mutation of the Ca ²⁺ Channel β Subunit Gene <i>Cchb4</i> is Associated with Ataxia and Seizures in the Lethargic (<i>lh</i>) Mouse", Cell, 88:385-392, 1997
	34	Fletcher et al., "Absence Epilepsy in Tottering Mutant Mice is Associated with Calcium Channel Defects", Cell, 87:607-617, 1996
	35	Wang et al., "Structural Requirement of the Calcium-channel subunit $\alpha 2\delta$ for Gabapentin Binding", Biochem. J., 342:313-320, 1999
	36	Stefani et al., "Gabapentin Inhibits Calcium Currents in Isolated Rat Brain Neurons", Neuropharmacology, 37:83-91, 1998
	37	Burgess & Noebels, "Single Gene Defects in Mice: The Role of Voltage-dependent Calcium Channels in Absence Model", Epilepsy Research, 36:111-122, 1999
	39	Needleman & Wunsch, "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", J. Mol. Biol., 48:443-453, 1970
	39	Smith & Waterman, "Comparison of Biosequences", Advances in Applied Mathematics, 2:482-489, 1981
	40	Rothenberg, M., et al., "Oligodeoxynucleotides as Anti-sense Inhibitors of Gene Expression: Therapeutic Implications", Journal of the National Cancer Institute, 81(20):1539-1544, 1989
	41	Nielsen, P. E., et al., "Peptide Nucleic Acids (PNAs): Potential Anti-sense and Anti-gene Agents", Anti-Cancer Drug Design, 8:53-63, 1993
	42	Mizushima & Nagata, "pEF-BOS, a Powerful Mammalian Expression Vector", Nucleic Acids Research, 18(17):5322, 1990
	43	Demoulin et al., "A Single Tyrosine of the Interleukin-9 (IL-9) eceptor is Required for STAT Activation, Antiapoptotic Activity, and Growth Regulation by IL-9", Molecular and Cellular Biology, 16(9):4710-4716, 1996
	44	Gregoriadis, G., "Liposomes for Drugs and Vaccines", Trends in Biotechnology, 3(9):235-241, 1985

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/553,117
				Filing Date	October 13, 2005
				First Named Inventor	Aiyar et al.
				Group Art Unit	
				Examiner Name	
Sheet	5	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	45	Hyrup, B. et al., "Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications", Bioorganic & Medicinal Chemistry, 4(1):5-23, 1996
	46	Perry-O'Keefe et al., "Peptide Nucleic Acid Pre-gel Hybridization: An Alternative to Southern Hybridization", Proc. Natl. Acad. Sci., 93:14670-675 (1996)
	47	Finn, P. J. et al., "Synthesis and Properties of DNA-PNA Chimeric Oligomers", Nucleic Acids Research, 24(17):3357-3363, 1996
	48	Mag, M. et al., "Synthesis and Selective Cleavage of Oligodeoxyribonucleotides Containing Non-chiral Internucleotide Phosphoramidate Linkages", Nucleic Acids Research, 17(15):5973-5988, 1989
	49	Petersen, K. H. et al., "A PNA-DNA Linker Synthesis of N-((4,4'-Dimethoxytrityloxy)Ethyl)-N-(Thymin-1-Ylacetyl)Glycine", Bioorganic Medicinal Chemistry Letters, 5(11):1119-1124, 1995
	50	Letsinger et al., "Cholesteryl-conjugated Oligonucleotides: Synthesis, Properties, and Activity as Inhibitors of Replication of Human Immunodeficiency Virus in Cell Culture", Proc. Natl. Acad. Sci., 86:6553-6556, 1989
	51	Dahiyat & Mayo, "De Novo Protein Design: Fully Automated Sequence Selection", Science, 278:82-87, 1997
	52	Lin et al., "Identification of Functionally Distinct Isoforms of the N-Type Ca ²⁺ Channel in Rat Sympathetic Ganglia and Brain", Neuron, 18:153-166, 1997
	53	Henikoff & Henikoff, "Amino Acid Substitution Matrices from Protein Blocks", Proc. Natl. Acad. Sci., 89:10915-10919, 1992
	54	Kozber, J. et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies", J. of Immunology, 133(6):3001-3005, 1984
	55	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas", Monoclonal Antibody Production Techniques & Applications, Marcel Dekker Inc., New York, p. 51-63, 1987
	56	Jakobovits et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-chain Joining Region Blocks B-cell Development and Antibody Production", Proc. Natl. Acad. Sci., 90:2551-2555, 1993
	57	Clark, W. R., The Experimental Foundations of Modern Immunology, Fourth Edition, John Wiley & Sons, New York, 1991
	58	Better et al., "Escherichia Coli Secretion of an Active Chimeric Antibody Fragment", Science, 240:1041-1043; 1988
	59	Liu et al., "Chimeric mouse-human IgG1 Antibody That Can Mediate Lysis of Cancer Cells", Proc. Natl. Acad. Sci., 84:3439-3443, 1987

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/553,117	
			Filing Date	October 13, 2005	
			First Named Inventor	Aiyar et al.	
			Group Art Unit		
Examiner Name					
Sheet	6	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	60	Oi et al., "Chimeric Antibodies", Bio Techniques, 4(3):214-220, 1986
	61	Ward et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted From <i>Escherichia Coli</i> ", Nature, 341:544-546, 1989
	62	Lazareno & Birdsall, "Pharmacological Characterization of Acetylcholine-stimulated [35S]-GTPγS Binding Mediated by Human Muscarinic m1-m4 Receptors: Antagonist Studies", Br. J. Pharmacol., 109:1120-1127, 1993
	63	Coward, P. et al., "Chimeric G Proteins Allow a High-Throughput Signaling Assay of Gi-Coupled Receptors", Analytical Biochemistry, 270:242-248, 1999
	64	Sebastian Lazareno, "Measurement of Agonist-Stimulated [35S]GTPγS Binding to Cell Membranes", Methods in Molecular Biology, 106:231-245 (1999)
	65	Zlokarnik et al., "Quantitation of Transcription and Clonal Selection of Single Living Cells with β-Lactamase as Reporter", Science, 279:84-88, 1998
	66	Wainscott et al., "Pharmacological Characteristics of the Newly Cloned Rat 5-Hydroxytryptamine 2F Receptor", Mol. Pharmacol., 43:419-426, 1992
	67	Fields, S. and Song, O., "A Novel Genetic System to Detect Protein-protein Interactions", Nature, 340:245-246, 1989
	68	Ho et al., "Dimeric Ligands Define a Role for Transcriptional Activation Domains in Reinitiation", Nature, 382:822-826, 1996
	69	Licita & Liu, "A Three-hybrid Ssystem for Detecting Small Ligan-Protein Receptor Interactions", Proc. Natl. Acad. Sci., 93:12817-12821, 1996
	70	Young et al., "Identification of a Calcium Channel Modulator Using a High Throughput Yeast Two-hybrid Screen", Nature Biotech, 16:946-950, 1998
	71	Wahl et al., "Improved Radioimaging and Tumor Localization with Monoclonal F(ab')2, Journal of Nuclear Medicine, 24(4):316-325, 1983
	72	Mishina et al., "Location of Functional Regions of Acetylcholine Receptor α-subunit by Site-directed Mutagenesis", Nature, 313:364-369; 1985
	73	Noda et al., "Expression of Functional Sodium Channels From Cloned cDNA", Nature, 322:826-828
	74	Price, C. M., "Fluorescence In Situ Hybridization", Blood Rev., 7:127-134, 1993

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		COMPLETE IF KNOWN			
		Application Number	10/553,117		
		Filing Date	October 13, 2005		
		First Named Inventor	Aiyar et al.		
		Group Art Unit			
		Examiner Name			
Sheet	7	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	75	Trask, B. J., "Fluorescence <i>in situ</i> Hybridization: Applications in Cytogenetics and Gene Mapping", Trends Genet., 7(5):149-154, 1991
	76	Egeland, J. et al., "Bipolar Affective Disorders Linked to DNA Markers on Chromosome 11", Nature, 325:783-787, 1987
	77	D'Eustachio P. et al., "Somatic Cell Genetics and Gene Families", Science, 220:919-924, 1983
	78	Verma et al., Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, 1989
	79	Fan, Y. et al., "Mapping Small DNA Sequences by Fluorescence <i>in situ</i> Hybridization Directly on Banded Metaphase Chromosomes", Proc. Natl. Acad. Sci., 87:6223-6227, 1990
	80	Gatti, R. A. et al., "Localization of an Ataxia-telangiectasia Gene to Chromosome 11q22-23", Nature, 336:577-580, 1988
	81	Lichtenstein, C., "Anti-sense RNA as a Tool to Study Plant Gene Expression", Nature, 333:801-802, 1988
	82	Cohen, Jack S., "Designing Antisense Oligonucleotides as Pharmaceutical Agents", Trends in Pharm. Sci., 10:435-437, 1989
	83	Weintraub, Harold M., "Antisense RNA and DNA", Scientific American, 262:40-46, 1990
	84	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents", Science, 247:1222-1225, 1990
	85	Maddox, D. E. et al., "Elevated Serum Levels in Human Pregnancy of a Molecule Immunohistochemically Similar to Eosinophil Granule Major Basic Protein", J. Exp. Med., 158:1211-1226, 1983
	86	Melby, P. C. et al., "Quantitative Measurement of Human Cytokine Gene Expression by Polymerase Chain Reaction", J. Immunological Methods, 159:235-244, 1993
	87	Duplaa, C. et al., "Quantitative Analysis of Polymerase Chain Reaction Products Using Biotinylated dUTP Incorporation", Analytical Biochemistry, 212:229-236 (1993)
	88	Brinster et al., "Factors Affecting the Efficiency of Introducing Foreign DNA Into Mice by Microinjecting Eggs", Proc. Natl. Acad. Sci., 82:4438-4442, 1985
	89	Brinster et al., "Somatic Expression of Herpes Thymidine Kinase in Mice Following Injection of a Fusion Gene into Eggs", Cell, 27:223-231, 1981

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merrick & Co., Inc., 8/24/2006

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

COMPLETE IF KNOWN


Sheet	8	of	8	Attorney Docket Number	MS0019P
-------	---	----	---	------------------------	---------


[illegible]Date
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/553,117
		Filing Date	October 13, 2005
		First Named Inventor	Aiyar, J. et al.
		Art Unit	T/B/A
		Examiner Name	T/B/A
Total Number of Pages in This Submission	11 + Refs	Attorney Docket Number	MS0019P

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please Identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Name	Vineet Kohli	Registration No. (Attorney/Agent)	37,003
Signature			Date
			2/28/2007

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on this date: 2/28/07			
Typed or printed name	Terri Schiffman		
Signature		Date	2/28/07



P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY V. Kohli		DATE 02/28/2007
CASE NUMBER/ MS0019P	SERIAL NUMBER 10/553,117	
DATE FILED 10/13/2005		
APPLICANT Aiyar et al.		
EXPRESS MAIL NO. -----		

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☐ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: COMMISSIONER FOR PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450

TERRI SCHIFFMAN
Name

Terri Schiffman
Signature

12/19/06
Date

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Aiyar et al.

Serial No.: 10/553,117 – Case No.: MS0019P

Filed: 10/13/2005

For: SPLICE VARIANTS OF HUMAN VOLTAGE-
GATED CALCIUM CHANNEL $\alpha 2\beta$ -2 SUBUNIT
DESIGNATED $\alpha 2\beta$ 2-A AND $\alpha 2\beta$ 2-B

Art Unit:

TBA

Examiner:

TBA

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450



SUBMISSION OF SEQUENCE STATEMENT

Sir:

Responsive to the Communication dated November 2, 2006, having a TWO month period of response, Applicants respectfully submit that the following statement be entered. In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the following statement is being submitted with the computer readable form of the Sequence Listing.

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.

DOCKETED
DEC 21 2006
LORI SCHEPISI

Application No.: 10/553,117
Amendment Date: 12/19/2006
Reply to Office Action of: 11/02/2006

AMENDMENTS TO THE SPECIFICATION:

Please enter the Sequence listing provided previously into the Specification.

Application No.: 10/553,117
Amendment Date: 12/19/2006
Reply to Office Action of: 11/02/2006

REMARKS/ARGUMENTS

Further to the Communication dated November 2, 2006, applicants submit the requested amendment to enter the sequence listing into the specification.

The Examiner is invited to contact Applicants' Attorney at the telephone number given below, if such would expedite the allowance of this application.

Favorable action is earnestly solicited.

Respectfully submitted,

By



Vineet Kohli
Reg. No. 37,003
Attorney for Applicant

MERCK & CO., INC.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3889

Date: _____

12/19/06

P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY V. Kohli		DATE 12/19/2006
CASE NUMBER/ MS0019P	SERIAL NUMBER 10/553,117	
DATE FILED 10/13/2005		
APPLICANT Aiyar et al.		
EXPRESS MAIL NO. -----		

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☐ INFORMATION DISCLOSURE STATEMENT
- ☐ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET
- ☒ SUBMISSION OF SEQUENCE STATEMENT

F4424

DOCKETED

DEC 21 2006

LORI SCHEPISI



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

MS0019P

U.S. APPLICATION NUMBER NO. 10/553,117	FIRST NAMED APPLICANT Jayashree Aiyar	ATTY. DOCKET NO. MS0019P
---	--	-----------------------------

PATENT DEPARTMENT

210
MERCK AND CO., INC
P O BOX 2000
RAHWAY, NJ 07065-0907

NOV 08 2006

VINEET KOHLI

DRAFTED

NOV 06 2006

LOH SCHEPTE

INTERNATIONAL APPLICATION NO. PCT/US04/12045	
I.A. FILING DATE 04/16/2004	PRIORITY DATE 04/18/2003

CONFIRMATION NO. 2168

371 FORMALITIES LETTER



OC000000021069529

Seq listing
(nmp) due
1-2-07
ans
12/19/06

Date Mailed: 11/02/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/553,117	PCT/US04/12045	MS0019P

FORM PCT/DO/EO/922 (371 Formalities Notice)

DOCKETED

DEC 21 2006

LORI SCHIEPISI